1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

1303GCC: Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma

This is a phase II study that combines Trastuzumab with Pertuzumab to see how it works in women age greater than 60 who have been diagnosed with HER2/neu overexpressed locally advanced and/or metastatic breast carcinoma.

Study Overview

• Status: Terminated
• Conditions: Metastatic Breast Cancer
• Intervention / Treatment: Drug: Trastuzumab plus Pertuzumab; Drug: Hormonal Therapy with Anastrozole and Fulvestrant; Drug: Chemotherapy with Eribulin

Detailed Description

Currently available standard therapies for HER2 overexpressed metastatic breast cancers (MBC) include treatments with chemotherapy or hormonal therapy, alone or in combination with medications that target HER2 gene, such as Trastuzumab or Pertuzumab. This study will examine the effect of treating HER2 overexpressed MBC with the combination of Trastuzumab plus Pertuzumab, without hormonal or chemotherapy, as a first line treatment. If patients progress on this treatment, they will receive hormonal or chemotherapy in addition to the Trastuzumab plus Pertuzumab treatment. The objective is to see how the overall response rate for this treatment compares to other first line treatments in the same patient population.

• Study Type: Interventional
• Enrollment (Actual): 2
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • University of Maryland Marlene & Stewart Greenebaum Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Women ≥60 Years of Age.
2. Histologically confirmed, locally advanced (T4 primary tumor and stage IIIB or IIIC disease) or metastatic breast cancer that progressed after treatment with standard treatment regimens in the adjuvant or neoadjuvant setting.
3. Prior treatment with trastuzumab and/or lapatinib in the neo-adjuvant or adjuvant setting is allowed but not required. Lapatininb has to be discontinued > 21 days before the initiation of the T+P study treatments.
4. Up to 3 prior chemo regimens for treatment of metastatic disease are allowed as long as the study subject is acceptable for study treatment with chemo required on this study in cohort 2 at progression on T+P.
5. Patients may have had prior hormonal therapy with any hormonal agents as per section 3.1.5 of this protocol.
6. Zometa or denosumab can be continued as per standard of care as long as started before the study treatment is started.
7. HER2 positive breast cancer, as defined in Section 3.3 of this protocol
8. Must have measurable or evaluable disease according to RECIST 1.1 criteria.
9. Lab values obtained ≤7 days prior to registration as indicated in 3.1.9 of this protocol.
10. ECOG Performance Status (PS) of 0, 1 or 2.
11. LVEF at least 50% as determined by MUGA or ECHO.
12. Life expectancy >3 months.
13. Written informed consent.
14. Willingness to return to study site for treatment and follow-up.
15. Normal QTc interval defined on EKG as QTc ≤ 440 msec.
16. Postmenopausal women defined in section 3.1.16 of this protocol.

Exclusion Criteria:

1. Stage III or IV cancer, other than breast cancer, in ≤5 years prior to registration.
2. Actively being treated for other malignancy.
3. New York Heart Association Class III or IV cardiovascular disease.
4. History of coronary heart failure (CHF)
5. Current use of drugs known to prolong the QTc interval including Class Ia and III antiarrhythmics or history of congenital long QTc syndrome.
6. Evidence of active brain metastasis including leptomeningeal involvement.
7. Major surgery, chemotherapy, hormonal or immunologic therapy ≤3 weeks prior to registration.
8. Radiotherapy ≤3 weeks prior to registration, except if to a non-target lesion only.
9. Prior treatment with Pertuzumab, Eribulin, Fulvestrant or Anastrozole.
10. Uncontrolled illness.
11. Co-morbid systemic illnesses or other severe concurrent disease. See section 3.2.11.
12. Currently receiving treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered.
13. Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be HIV positive.
14. International normalized ratio (INR), activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) >1.5 × ULN (unless on anticoagulation medication)
15. Receipt of intravenous (IV) antibiotics for infection within 7 days prior to enrollment into the study.
16. Current chronic daily treatment with corticosteroids. See section 3.2.16 of this protocol.
17. Known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies.
18. History of receiving any investigational treatment within 28 days prior to enrollment into the study.
19. Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1: T+P; Trastuzumab plus Pertuzumab as first line treatment for HER2 overexpressed Metastatic Breast Cancer (without hormonal therapy or chemotherapy)	Drug: Trastuzumab plus Pertuzumab
Experimental: Cohort 2 - Arm A; Hormonal Therapy with Anastrozole and Fulvestrant in addition Trastuzumab plus Pertuzumab for women who progressed on T+P alone, and who are ER/PR +	Drug: Trastuzumab plus Pertuzumab; Drug: Hormonal Therapy with Anastrozole and Fulvestrant; Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days; Other Names: Anastrozole (Arimidex); Fulvestrant (Faslodex)
Experimental: Cohort 2 - Arm B; Chemotherapy with Eribulin in addition to Trastuzumab plus Pertuzumab for women who progressed on T+P alone and who are ER/PR -	Drug: Trastuzumab plus Pertuzumab; Drug: Chemotherapy with Eribulin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR) in Patients	Defined as the total of complete response (CR) defined as a disappearance of all target lesions, partial response (PR) defined as >= 30% decrease in the sum of the longest diameter of target lesions, and stable disease (SD) >= 27 weeks among the total number of participants as defined by the Response Evaluation in Solid Tumors (RECIST) 1.1 response criteria.	Participants were staged every two cycles for the duration of the study participation ( CR+PR+SD=ORR), up to 11 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival (PFS)	Progression Free Survival in treatment cohorts 1 and 2 as well as arms A and B from the time on study until progression of disease or death	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 11 months
Overall Survival (OS)	Overall survival (OS) in treatment cohorts 1 and 2 as well as arms A and B from the time on study until death	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion, an average of 2 years.
Number of Participants With Treatment Related Adverse Events as Assessed by CTCAE v4.0	the safety and tolerability of Trastuzumab and Pertuzumab alone and in combination with hormonal therapy or single agent chemotherapy. in HER2+ MBC patients	Participants were followed during the study and for 30 days after completion of the study treatment, up to 12 months
Quality of Life Via Patient-reported Outcomes	quality of life and treatment side effects via patient-reported and investigator reported outcomes	Duration of study, participants were followed every cycle up to 11 months.

Collaborators and Investigators

• Sponsor: University of Maryland, Baltimore
• Collaborators: Genentech, Inc.

Study record dates

Study Major Dates

• Study Start: January 1, 2014
• Primary Completion (Actual): November 1, 2015
• Study Completion (Actual): January 1, 2016

Study Registration Dates

• First Submitted: November 21, 2013
• First Submitted That Met QC Criteria: November 26, 2013
• First Posted (Estimate): December 4, 2013

Study Record Updates

• Last Update Posted (Actual): May 27, 2022
• Last Update Submitted That Met QC Criteria: May 4, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: Elderly; Metastatic Breast Cancer; HER2 overexpressed
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Hormone Antagonists; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Estrogen Receptor Antagonists; Trastuzumab; Fulvestrant; Anastrozole; Pertuzumab
• Other Study ID Numbers: HP-00054959; 1303GCC; GCC1303 (Other Identifier: University of Maryland Greenebaum Cancer Center)